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ABSTRACT 
Background: More than 166 000 women die annually from obstetric haemorrhage, with 
uterine atony being the most common causative factor (3). More than 50% of these deaths 
occur in Sub-Saharan Africa (4, 5). Synthetic oxytocin is integral in the prevention and 
management of postoperative post partum haemorrhage (PPH) and therefore it is essential 
for anaesthesiologists to have an adequate knowledge of this drug. 
Aim: The aim of the study was to describe the current knowledge and practise of the 
anaesthetists in the department of Anaesthesiology at the University of Witwatersrand 
(Wits), regarding Syntocinon® during caesarean section under spinal anaesthesia. 
Method: A validated questionnaire was distributed to anaesthetists working at Wits during 
departmental academic meetings in April 2015.  
Results: The results of the study showed that 60% of the participating anaesthetists had 
inadequate knowledge of IV Syntocinon® and that practice varied widely and was based on 
individual participants’ preference and was not consistent with international guidelines or 
protocols. 
Conclusion: Urgent staff education and implementation of a standardised practice guideline 
and protocol regarding usage and dosing of IV Syntocinon® is needed to prevent poor 
maternal outcomes and poor service delivery. 
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CHAPTER ONE 
OVERVIEW OF THE STUDY 
 Introduction 
This chapter will serve as an overview of the study and include the following: background, 
problem statement, aim and objectives, research assumptions, demarcation of study field, 
ethical considerations, research methodology, the significance of the study, validity and 
reliability of this study and study outline. 
 Background 
According to the World Health Organisation (WHO) more than 210 million women fall 
pregnant every year, of whom more than 20 million will experience pregnancy related illness 
and approximately  500 000 will die as a result of the complications of pregnancy and 
childbirth (1, 2). 
Internationally more than 166 000 women die from obstetric haemorrhage annually, with 
uterine atony being the most common causative factor (3). More than 50% of these deaths 
occur in Sub-Saharan Africa, the causes being widespread and include post-partum 
haemorrhage (PPH) (4, 5). Consequently uterotonic drugs such as synthetic oxytocin have 
become integral in the management and prevention of PPH (6-8).  
Synthetic oxytocin e.g. Syntocinon® is an uterotonic drug that is a synthetic nonapeptide 
identical to oxytocin, a hormone released by the posterior lobe of the pituitary. Synthetic 
oxytocin is the first line treatment for the management of PPH and other drugs are available 
for second line management. (7, 8) 
The Food and Drug Administration (FDA) has placed a black box warning on the correct 
usage and indication of Syntocinon® for usage during labour (9). Syntocinon® is associated 
with numerous adverse effects including severe hypotension, chest pain, myocardial 
ischemia, cardiac arrest as well as water intoxication due to its antidiuretic effects (8). 
Syntocinon® has a narrow therapeutic range in terms of maternal morbidity and a detailed 
knowledge of the pharmacology, dosage, route and rate of administration is essential (5). 
Internationally, guidelines regarding prevention and management of PPH have been 
developed by the World Federation of Societies of Anaesthesiologists (WFSA), the Royal 
College of Obstetricians and Gynaecologists (RCOG), the National Institute of Clinical 
Excellence (NICE), American Congress of Obstetricians and Gynaecologists, the Royal 
Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) and 
the South African Society of Anaesthesiology (SASA).  
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No guidelines could be identified regarding the administration of Syntocinon® during spinal 
in uncomplicated caesarean section but a few guidelines were identified for Syntocinon® 
dosing during PPH. 
International guidelines for the prevention and management of PPH vary in dose and 
method of Syntocinon® administration. Recent literature suggests that a lower dosage of 
Syntocinon® in the uncomplicated caesarean section is as effective as the dosage 
suggested by the various guidelines. (5, 8, 10-13)              
Jansen (14) is of the opinion that medication is an essential part of a doctor’s practice and 
therefore they are expected to have a comprehensive knowledge of medication. No doctor is 
allowed to prescribe or administer medication if they do not have an up-to-date knowledge of 
that medication.        
Doctors’ knowledge of medication in general is variable (15-19) .Two qualitative studies from 
India (17, 18) concluded that doctors, midwives, ‘traditional’ doctors and nurses had poor 
knowledge of the correct use of Syntocinon®. After an educational programme on the 
correct use of Syntocinon® Bolton et al (19) found that 23 % of doctors did not change their 
incorrect use of Syntocinon®.                                                                                                       
1.3 Problem statement 
Syntocinon® is a dangerous drug with a narrow therapeutic range in terms of maternal 
morbidity (3, 5, 11). Legally doctors should have comprehensive and up-to-date knowledge 
of medication that they prescribe and administer (14). 
 No specific protocol has been adopted by the Department of Anaesthesiology at the 
University of the Witwatersrand (Wits) for the administration of Syntocinon®.  Current 
knowledge and practises regarding Syntocinon® amongst Wits anaesthetists was unknown.  
1.4 Aim 
The aim of the study was to describe the current knowledge and practise of the 
anaesthetists in the Department of Anaesthesiology at Wits regarding Syntocinon® during 
caesarean section under spinal anaesthesia. 
1.5 Objectives 
The primary objectives of this study were to: 
 describe the anaethetists’ knowledge of Syntocinon® 
 describe anaethestists’ practise regarding Syntocinon®. 
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The secondary objectives were to: 
 describe the difference in knowledge between the medical officers, junior registrars, 
senior registrars and consultants 
 compare the knowledge between the junior doctors and the senior doctors. 
1.6 Research assumptions 
The following definitions will be used in this study: 
Oxytocin: refers to the synthetic oxytocin (Syntocinon®). 
Knowledge: refers to the medical knowledge a doctor possesses regarding Syntocinon®. 
Adequate Knowledge: attaining a score of 80 % or above in the knowledge section of the 
questionnaire. 
Practise: is the dosage, frequency, rate and method (bolus or continuous infusion) of 
Syntocinon® administration currently being used by the doctors. 
Anaesthetists: an anaesthetist refers to all medical officers, registrars and consultants 
currently working in the Department of Anaesthesiology at Wits. Interns and emergency 
medicine registrars working in the department at the time will be excluded. 
Medical Officer: is a licensed doctor practising anaesthesia under specialist supervision who 
form part of the Department of Anaesthesiology at Wits. Junior medical officers will be 
regarded as junior registrars and career medical officers will be regarded as consultants. 
Registrar: is a doctor that is in the process of obtaining a specialist anaesthesiology 
qualification, endorsed by the Health Professions Council of South Africa. A junior registrar is 
a registrar in anaesthesiology pre the part one exams. A senior registrar is a registrar in 
anaesthesiology post the part one exams. 
Consultants: any anaesthetist who has completed the required South African College of 
Medicine examinations, and all other criteria to become a specialist in anaesthesiology. 
Career medical officers will also be included in this category. 
Junior doctor: in this study refers to any medical officer and junior registrar (registrars pre 
part one exams) 
Senior doctor: in this study refers to any senior registrar (registrars who have completed part 
one exams) and consultant. 
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1.7 Demarcation of study field 
The study was conducted in the Department of Anaesthesiology at Wits, at Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH), Chris Hani Baragwaneth Academic 
Hospital (CHBAH), Helen Joseph Hospital (HJH), and Rahima Moosa Mother and Child 
Hospital (RMMCH).   
1.8 Ethical considerations 
Approval to conduct this study was obtained from the Postgraduate Committee and the 
Human Research Ethics Committee (Medical) of the University of the Witwatersrand. 
An information letter (Appendix 1) was provided to the participants explaining the purpose 
and process of the study. Consent was implied by accepting the invitation. Anonymity and 
confidentiality were ensured.  
This study was conducted according to the South African Good Clinical Practice Guidelines 
(20) and the Declaration of Helsinki (21). 
1.9 Research methodology 
A descriptive, prospective, contextual study design was used.The study population consisted 
of the anaesthetists working in the Department of Anaesthesiology at Wits. 
At the time that the study was conducted it was estimated that there were 228 anaesthetists 
working in the department. A biostatistician was consulted, and it was determined that if the 
power of the study was to be 80% (using EpiInfoTM version 6) a sample size of 116 
respondents was needed. 
A convenience sampling method was used. The questionnaire was presented at academic 
departmental meeting at each of the four individual hospitals, CHBAH, CMJAH, RMMCH 
and HJH. Doctors attending these meetings were approached for inclusion in the study. 
They were requested to only complete the questionnaire once. Inclusion criteria and 
exclusion criteria for study were defined. 
1.9.1 Data collection 
1.  Development of questionnaire 
No questionnaires assessing the appropriate administration of Syntocinon® were identified. 
A draft questionnaire based on a review of the literature was developed by the researcher 
with guidance from the co-supervisor, who is a specialist in the field of anaesthesiology and 
pharmacology. 
 
Marike De Jager      Student Number: 737758     October 2016 
 
Page 5 
 
 The self-administered questionnaire consisted of three sections.  
Section 1 requested demographic data 
      Section 2 consisted on knowledge questions 
            Section 3 addressed current practise regarding Syntocinon®. 
2. Data analysis 
A Microsoft ® Office Excel spreadsheet was used to capture the data. Data was analyzed 
using STATISTICA version 11. Descriptive and inferential statistics were used.  
1.10 Significance of the study 
Syntocinon® is used routinely in patients following delivery. This is a ‘black box drug’ and is 
associated with serious complication and therefore adequate knowledge when administering 
this drug is of utmost importance. Numerous studies (17-19) have shown that doctors have 
inadequate knowledge in regard to medication prescribed and administered.  
It was therefore imperative that the current knowledge of doctors in the Department of 
Anaesthesiology was determined. Since knowledge was found to be lacking, educational 
initiatives were implemented and a formal protocol should be developed and introduced in 
the department adhering to international guidelines. 
1.11 Validity and reliability 
Measures were taken to ensure the validity and reliability of the study. Validity emerges from 
the internal and external consistency and relevance of the questionnaire, whilst reliability 
refers to the quality of the questionnaire. 
The questionnaire (Appendix Two) underwent a validation procedure that accurately 
measured its objectives, regardless of the study population’s status, timing of response and 
different investigators. The elements used in the validation of the questionnaire were: 
construct validity and content validity.  
1.12 Study outline 
This study is presented as follows. 
Chapter One: Overview of the study. 
Chapter Two: Literature review. 
Chapter Three: Research methodology. 
Chapter Four: Results and discussion. 
Chapter Five: Summary, limitations, recommendations and conclusion. 
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1.13 Summary 
An overview of the study was presented in Chapter one. In the following chapter a review of 
the literature relevant to this study is presented.  
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Introduction 
The World Alliance for Patient Safety (22) states: “The main threats to patient safety 
worldwide are inadequate numbers of equitably distributed qualified health care providers 
and incomplete knowledge about safe practise.” 
Globally PPH is the leading cause of maternal mortality and recent studies (3, 5, 11, 23) 
have shown that the rates of PPH due to uterine atony are increasing. Prevention and 
management of PPH is crucial to improve maternal safety. 
Another of the aspects that contribute to safe practise is the knowledge and correct use of 
medication. Knowledge of physicians seems to be varied and often lacking in regards to 
administration, cost, pharmacokinetics and pharmacodynamics of medication. (24-27)   
In this chapter the main discussion will be of oxytocin. The FDA has recently placed a black 
box warning on the correct indication for use and use during labour (28). Oxytocin is the first 
line treatment in prevention and management of PPH, therefore the literature review will 
begin with a brief overview of PPH. 
The discussion on Oxytocin will include the history, mode of action, route of administration 
complications, dosage and guidelines for administration. Lastly there will be a discussion of 
doctors’ knowledge of medication in general and oxytocin specific. 
2.2. Post-partum haemorrhage (PPH) 
Globally PPH is the leading cause of maternal mortality and recent studies have shown that 
the rates of PPH due to uterine atony are increasing (11). Prevention and management of 
PPH is crucial to improve maternal safety (5-7). 
2.2.1 Definition 
PPH is defined as being an estimated blood loss of 500 ml or more during vaginal delivery 
and more than 1000 ml for a caesarean delivery. Primary PPH develops within 24 hours of 
delivery and is due to uterine atony; retained placenta; genital tract trauma; placenta accreta, 
increta or percreta; uterine inversion; or coagulopathy.  
Secondary PPH is relatively infrequent, develops more than 24 hours after delivery, and is 
ascribed to subinvolution of the placental site, retained products of conception, infection, or 
inherited coagulation defects. (29) 
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2.2.2 Incidence 
Caesarean section is one of the most commonly performed major operations in women 
throughout the world, with rates escalating to between 20-30% in developed countries yearly 
(30, 31).  
According to WHO more than 500 000 women die as a result of the complications of 
pregnancy and childbirth with PPH due to uterine atony being the most causative factor (1, 
2, 5). Internationally obstetric haemorrhage continues to be the most common avoidable 
cause of maternal death (6). 
Between 1994 and 2006, rates of PPH have increased by 30% in the United States of 
America, almost entirely attributable to increases in postpartum uterine atony and accounts 
for 13 % of all maternal deaths (29).According to the Royal Australian and New Zealand 
College of Obstetricians and Gynaecologists (RANZCOG) the incidence of PPH in Australia 
is between 5 and 15% yearly (23).In India it was suggested that between 31% and 34% of 
maternal deaths were due to PPH (32). 
In South Africa, during the period 2008-2010, there were 688 maternal deaths as a result of 
obstetric hemorrhage. This represented a  significant increase (32,4%) in the Institutional 
Maternal Mortality Rate related to obstetric haemorrhage, from 18.82/ 100 000 live births in 
2005-2007, to 24.91/ 100 000 live births in 2008-2010. (6, 33)  
2.2.3 Risk Factors 
According to the RCOG guideline causes and risk factors for PPH are related to:  
 tone (abnormalities of uterine contraction) 
 tissue (retained products of conception) 
 trauma (of the genital tract) 
 thrombin (abnormalities of coagulation). (34) 
The most common cause for primary PPH is uterine atony, but other causes such as 
retained products, vaginal lacerations, ruptured uterus, broad ligament haematoma, 
extragenital bleeding and uterine inversion have also been implicated. Secondary PPH is 
often associated with endometritis. (34, 35) 
2.2.4 Management of PPH= 
An uterotonic agent such as oxytocin is used to induce contraction of the uterus, it has also 
become the first line agent in the management and prevention of PPH.  
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Second line agents are available such as ergot alkaloids and prostaglandins but this study 
will focus on the use of oxytocin. (5, 30)  
Guidelines will be discussed after oxytocin administration as there is overlap between the 
topics.                                                                        
2.3. Oxytocin  
2.3.1 History 
Historically the posterior pituitary gland ‘extract’ has been used in the presence of PPH since 
1901, and in 1928, Kamm et al (13) separated this ‘extract’ into oxytocin and a vasopressor.  
Oxytocin in its modern day form was first discovered by Sir Henry Dale and was also the first 
polypeptide hormone synthesised by Du Vigneaud, in 1953 (5, 36).  In the late 1960s 
O’Driscoll advocated the use of oxytocin intrapartum as a component of active management 
of labour (36). 
2.3.2 Mode of action: 
The term oxytocic (or oxytocinergic) specifically applies to those drugs where the oxytocin 
receptor is the binding and activation site. Oxytocin is the most widely used uterotonic used 
for caesarean section and prophylactic routine use of oxytocin has been shown to reduce 
the incidence of PPH by 40%. (37, 38) 
Oxytocin is a nonapeptide hormone produced by the paraventricular nuclei of the 
hypothalamus and is stored and released mainly by the posterior lobe of the pituitary, but 
also at other sites namely the corpus luteum, Leydig cells, adrenal medulla and retina (5).  
Structurally oxytocin is very similar to anti-diuretic hormone (ADH), differing only in the 
substitution of two amino acids, explaining both its anti-diuretic actions and vasoactive 
properties in high doses. Both hormones are degraded and broken down by the same 
aminopeptidases.(13) 
Oxytocin binds to a G-protein (oxytocin receptor) on the surface of the uterine myocyte, 
resulting in the generation of diacylglycerol (DAG) and inositol tri-phosphate (IP3) via the 
action of phospholipase C on phosphatidyl-inositol biphosphate (5, 39).  DAG stimulates 
prostaglandin synthesis, and IP3 stimulates the release of calcium from the endoplasmic 
reticulum (5). Calcium released from the endoplasmic reticulum binds to, and activates, 
calmodulin, the calcium calmodulin complex then binds to myosin light chain kinase (MLCK), 
enabling phosphorylation of the short chain of myosin and causing formation of adenosine 
triphosphate (ATP) and muscle contraction (5, 7). 
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Oxytocin also activates the COX-2 via a further G-protein interaction thereby stimulating 
prostaglandin synthesis (5). There are oxytocin receptors in the uterus, and receptors are 
also located in the mammary, endothelial, and central nervous tissue (39, 40). The 
concentration of myometrial receptors and myometrial gap junctions increase as gestation 
advances, increasing sensitivity to oxytocin (5). The effect of oxytocin on endothelial 
receptors produces a calcium-dependant vasodilatory effect via stimulation of the nitric oxide 
pathway, thus producing hypotension and cardiovascular side effects (40). Most importantly 
it causes contraction of the uterus, which is why it is so useful in the management of PPH (8, 
37, 38).                                                                               
Oxytocin causes contraction of the myo-epithelial cells surrounding the mammary alveoli, 
thereby facilitating lactation in women experiencing difficulties with breast feeding (41). It 
also has a role in cardiovascular regulation, in sexual and maternal behaviour, and in 
memory and the regulation of food and fluid intake. Oxytocin has been shown to cause the 
release of atrial and brain natriuretic peptide, and in animal studies have shown to have 
negative inotropic effects. (5) 
During pregnancy the uterine oxytocin receptors increase progressively and reach a peak at 
term. In late pregnancy prior to the onset of labour the amount of oxytocin receptors are on 
average 12 times higher than in early pregnancy and about 80 times higher than in the non-
pregnant uterus. The plasma concentration of oxytocin is similar during pregnancy and 
during labour; however, there is a significant increase in the plasma concentration during the 
last part of the second stage of labour. (32) 
The non-labouring uterus remains more sensitive to oxytocin at term and thus low dose 
oxytocin at this stage might have optimum efficacy, without the deleterious effects of high 
dosages (32). During the onset of labour, uterine sensitivity to oxytocin increases and 
oxytocin receptors express diffusely and heterogeneously. By increasing the dosage of 
oxytocin administered it could be assumed that more effective uterine contraction would take 
place but, the response will be inadequate. (32) This is due to the fact that with continuous 
exposure to oxytocin the human myometrial cells’ oxytocin receptors lose their capacity to 
respond to the oxytocin by becoming desensitised and reduced. The oxytocin induced 
desensitization is dependent upon the duration of oxytocin exposure and occurs over a 
clinically relevant time frame of approximately 4.2 hours. Consideration should be given to 
the alternate pathway of uterotonic medications such as ergot derivatives, carboprost and 
misoprostol. (32, 38) 
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Oxytocin is released by the neurohypophysis in intermittent bursts determined by 
neurosensory stimuli, such as cervical dilatation, stimulation of the inferior genital tract, 
suckling by infant on the nipple and an increase in plasma osmolality (13). 
2.3.3 Route of administration 
Oxytocin may be administered intravenously (IV), intramuscularly (IM), or via the umbilical 
vein, buccal or nasal mucosa. The IV route has been in question due to the hemodynamic 
side effects; however the IM route has a much slower onset but lower side effect profile. (41, 
42) 
To diminish adverse effects when administering oxytocin as an IV bolus ‘slow’ dosing is 
advisable, but the most adequate speed of infusion has not yet been determined. (13)  
Synthetic oxytocin such as Syntocinon® is the most widely used oxytocic, and it has a short 
half-life of approximately 3-5 minutes (8, 41, 42). It is often used as an IV bolus, but an 
infusion may be used to maintain uterine contraction especially in managing PPH (8, 41, 42). 
It can also be given as an  IM injection, with the myotonic effects appearing on the uterus in 
3-7 minutes and persisting for 30-60 minutes (42).  
The timing of oxytocin administration remains debatable. Oxytocin intra-operatively can be 
administered before placental separation or after expulsion. Optimal timing is unclear and 
has not been evaluated in the literature. A randomized controlled trial comparing the different 
timing of administration did not find any difference between the groups in terms of blood loss 
and risk of placental retention (43). Most randomized trials administered oxytocin before 
placental separation (44). 
Oxytocin clearance is via the kidneys and the liver and only a small fraction is excreted 
unchanged in the urine (13). 
2.4 Guidelines and dosages 
Internationally guidelines and protocols exist in the management of certain medical 
disorders, but often physicians do not follow guidelines. Physician adherence to guidelines is 
critical to the improvement of outcomes in patients, but following a guideline without 
adequate knowledge of the drug has also proven to be disastrous to patient outcomes. (23, 
34, 45-47)  
 
Currently no guideline exists on the administration of oxytocin for uterine atony in 
uncomplicated caesarean section internationally, although guidelines do exist in the 
management of PPH (6, 34, 37, 46, 47). 
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According to the ESMOE guidelines and the monograph of the management of PPH, the 
majority of PPH related deaths are preventable. The monograph also gives clear guidelines 
to doctors, midwives and paramedics as to how to prevent and manage women with 
massive PPH.(48)  
SASA has no guidelines specific to use of oxytocin in uncomplicated caesarean section. (46) 
The World Federation of Societies of Anaesthesiologists (WFSA) uses the guideline of a 
slow IV bolus of 5 U that can be repeated if needed, infusion can be commenced using 10 
U/hr for 4 hours. (49) 
The Royal College of Obstetricians and Gynaecologists (RCOG) and National Institute of 
Clinical Excellence (NICE) recommend the use of a bolus of 5 U oxytocin by slow IV 
injection with the option of repeated dosages, if further uterine atony continuous an oxytocin 
infusion of 40 U in 500 ml Hartmann’s solution at a rate of 125 ml/hour is recommended. (8, 
35)  
The American Congress of Obstetricians and Gynaecologists recommends 20 U in 500 ml 
Ringer’s lactate at 125 ml/hour. There should also be a low threshold when using second-
line agents to avoid side-effects. (50) 
The guideline for the management of PPH from the Society of Obstetricians and 
Gynaecologists of Canada is the administration of oxytocin either IM or IV in small doses 
(unspecified amount) and if bleeding still continues 20 U of oxytocin in 1 litre of Ringer’s 
Lactate with no infusion rate specified. It also advises that oxytocin can be administered 
intra-myometrially 10 U in circulatory collapse (51). 
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists 
(RANZCOG) guideline recommends the use of oxytocin by slow IV injection or infusion but 
no dosage or infusion rate is specified (23). 
SASA has no prescribed guideline on the management of PPH, but according to the South 
African Saving Mothers Report of 2008-2010 the guideline for the management of PPH  is a 
2.5 U bolus IVI  of oxytocin followed by an IV infusion of 10 U of Syntocinon® in 1 litre of 
Normal Saline, no dosing rate of infusion is given (6). 
According to the South African Society of Obstetricians and Gynaecologists, the 
management guideline for PPH advises an IV infusion of 20 U of oxytocin with no rate of 
infusion specified (52). 
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According to the national ESMOE guidelines for district and regional hospitals, one should 
give 2,5 U oxytocin IV slowly over 1 minute and infuse 20 U of oxytoxin in 1 litre of clear fluid 
over eight hours.(53) 
In comparison to anaesthetic guidelines, obstetric guidelines advise much higher dosages of 
oxytocin, not necessarily in keeping with recent anaesthetic literature. (52) 
Recent studies have shown that lower dosages of oxytocin were as effective at contracting 
the uterus as higher dosages and in view of multiple side effects it is desirable to administer 
the lowest effective dose in a stable manner (5, 54). 
A comparison of intravenous boluses of oxytocin, either 2 U or 5 U showed less marked 
heart rate and blood pressure changes after 2 U, with no difference in requests for additional 
uterotonic agents. This study also found that a slow infusion of 5 U of oxytocin compared to 
a fast bolus of 5 U produced less cardiovascular instability (5, 12). The efficiency of slow 
infusions in terms of uterine contraction is difficult to assess other than by subjective means 
clinically by the obstetricians (5). 
A study done during 2010 at the Lucile Packard Children’s Hospital in California found that 
the routine use of 5 U of oxytocin was no longer recommended since adequate uterine 
contraction could be achieved with lower doses of oxytocin (0.5- 3U), therefore also 
decreasing the risk of cardiovascular side effects with higher doses. (54) 
In an observational study, oxytocin was used in incremental doses of 0.1-0.5 U during 
caesarean section in patients with advanced cardiac disease that included cardiomyopathy, 
congenital and valvular heart disease. There was acceptable hemodynamic stability, 
although even these small doses were associated with transient changes in blood pressure 
and cardiac output.(40) 
The dose and rate of intravenous infusion of oxytocin after delivery during caesarean section 
remains controversial and there have only been four dose-finding studies (5, 54-57). 
The first of these is a study by Carvalho et al (57) that reported the effective dose (ED90) for 
oxytocin was 0.35 U to order to achieve successful uterine contraction during elective 
Caesarean section. The up-down sequential method of establishing effective mean dose 
was used.  
Butwick et al (54) conducted a double-blinded, randomised control study to examine the 
effects of four different doses (0,5 U; 1.0 U; 3 U and 5 U) and a placebo. 
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Seventy-three per cent of patients had adequate contraction with placebo or low oxytocin 
doses. The authors concluded that an oxytocin dose of 0.5-3 U was adequate to achieve 
uterine contraction. 
The third study by Balki et al (56) carried out an emergency Caesarean section for labour 
arrest. The ED90 was reported to be 2.99 u, the highest dose needed to achieve adequate 
uterine contraction in non-elective cases. 
There is little evidence for the optimal infusion rate following the initial bolus dose of 
oxytocin. Using an up-down sequential allocation with a biased coin design, George et al 
(55) estimated the ED90 of an oxytocin infusion for adequate uterine contraction at 3 min 
after cord clamping, in patients undergoing elective caesarean section. The estimated ED90 
was 0.29 U/min (95% Cl= 0.15-0.43 U/min), i.e. approximately 15 U of oxytocin in 1 litre of IV 
fluid administered over one hour. 
Oxytocin is much less active as an antidiuretic when the infusion rate is less than 45 
milliunits/min and thus guidelines and protocols for the prophylaxis of PPH should be 
restricted to an infusion rate lower than this (5). 
Hypovolaemic patients should be managed with great care, as adverse effects with oxytocin 
infusion are often greater than in well resuscitated patients. (5) 
In a recent study by Langaester et al (40), with the administration of a second dose of 
oxytocin the cardiovascular response was diminished due to the desensitisation of the 
oxytocin receptors. Oxytocin receptors concentration decreased 60 times during oxytocin 
augmented labour and 300 times during oxytocin induced labour. Prior exposure of oxytocin 
to a rat’s myometrium suggests that efficacy falls inversely to the concentration, and this was 
independent to time of exposure. Thus repeated doses of oxytocin become increasingly 
ineffective and second line uterotonic agents should be administered. (5) 
Some studies have also been done by obstetricians with high doses of oxytocin IV infusions, 
as shown by Munn et al (13) that demonstrated that the continual infusion (2,667 
milliunits/minute) of high doses of oxytocin (80 U in 500 ml of Ringer’s Lactate) was superior 
to low doses (10 U in 500 Ml of Ringer’s lactate at 333 milliunits/minute) in the prevention of 
PPH in caesarean section. In a more recent study  in 2012, Roach et al (58) used dosages 
between 5 U and a 100 U of oxytocin with administration time varying from 5 seconds to 30 
seconds IV bolus to 8 hour IV infusion in 500 ml Ringer’s lactate. The higher infusion doses 
of 80 U in 500 ml appeared to be more effective at reducing PPH during caesarean section 
than lower dosages.  
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However, in both studies no mention is made of any side effects demonstrated by the 
patients on high dosages of oxytocin, and no mention was made of monitoring done for 
cardiovascular instability during infusions (13, 58). 
2.5 Complications 
In the Report on Confidential Enquiries into Maternal Deaths in South Africa of 2004-2007, 
two deaths were reported where oxytocin played a contributory part (5). Oxytocin also 
played a role in at least one maternal death in the UK based on the Confidential Enquiry into 
Maternal Deaths in 1997-1999, and the Food and Drug Administration (FDA) has placed a 
black box warning on the correct usage and indication for usage during labour (9). A black 
box warning (or boxed warning) is a type of warning issued by the FDA to a prescribed 
drug’s label and is designated to call attention to serious and life threatening risks (28). 
Oxytocin is therefore a dangerous drug and adequate knowledge when administering this 
drug is of utmost importance. Oxytocin is the most recent addition to the Institute for Safe 
Medication Practises’ list of only 12 high-alert medications that carry a heightened risk of 
causing harm when used erroneously (15). 
Oxytocin is associated with numerous side effects especially when given IV as a rapid bolus 
(38). Side effects include (5, 9, 11, 59-62): 
 cardiovascular (hypotension, chest pain, myocardial ischemia and cardiac arrest) 
 headache  
 flushing 
 nausea and vomiting 
 water intoxication with hyponatremia 
 pulmonary oedema 
 seizures and coma 
 foetal adverse effects. 
2.5.1 Cardiovascular 
It was demonstrated that the rapid administration of a bolus of oxytocin IV could reduce 
mean arterial pressure by up to 30%, 10 to 40 seconds after the injection, lasting up to 210 
seconds. (63)  
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The hypotension experienced with a rapid bolus dose of IV oxytocin may be due to 
numerous factors namely: 
 Vasodilatation of the capacitance vessels decreasing venous return (59); 
 Transient relaxation of the vascular smooth muscle cells via the calcium dependant 
stimulation of the nitric-oxide pathway (5) or; 
 The effect of the preservative in some formulations of synthetic oxytocin, 
chlorbutanol, on atrial myocytes which stimulates the release of atrial natriuretic 
peptide and brain natriuretic peptide (64).  
Patients with a normal volume status, heart valves and pulmonary vasculature usually 
respond to this hypotension with a compensatory increase in heart rate and stroke volume 
(65). Thus patients that are normovolaemic with no cardiac disorders tolerate the 
vasodilatation after a bolus or excessive dosage administration of oxytocin well. However, a  
large bolus of oxytocin may be fatal in patients with hypovolaemia or other pre-existing 
cardiac disorders (13). 
A method of obtunding the adverse hemodynamic effects of oxytocin was investigated by 
Dyer et al (11).  
A 2.5 U oxytocin bolus at elective caesarean delivery under spinal anaesthesia was given in 
combination with an 80 mcg dose of phenylephrine IV. The phenylephrine dose did not 
abolish the hemodynamic effects but managed to obtund them, and the author suggested 
that the administration of phenylephrine prior to oxytocin might be even more effective.  
The vasodilatation of the capacitance vessels although temporary, is much more prominent 
in the presence of general anaesthesia (13). 
Rapid bolus injection of oxytocin results in marked vasodilatation of arteries and capacitance 
vessels, thereby increasing cardiac output (up to two-fold) (59). Vasodilatation of 
capacitance vessels decreases venous return, leading to a fall in blood pressure, increase in 
heart rate and, in some patients, myocardial ischemia (59, 60). Patients presenting with 
hypovolaemia prior to surgery often respond more severely to a bolus of oxytocin with 
marked cardiovascular side effects which include cardiac arrest (5, 13, 32). 
In a study by Bhattacharya et al (32) it was found that a significant number of cardiovascular 
events occurred with a bolus regimen of the oxytocin in comparison with an infusion, where 
uterotonic effects were similar in both groups. It was also shown that in the bolus group, 
chest pain and ST-T segment depression were more frequent than in the infusion group of 
patients (29).  
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Gutkowska et al (66) showed that oxytocin receptors were demonstrated in all the chambers 
of the heart and that these receptors mediate the action of oxytocin to release atrial 
natriuretic peptide (ANP) which slows the heart and reduces its force of contraction. 
Tachycardia occurs commonly and can be compensatory (secondary to hypotension) or 
from stimulation of myocardial oxytocin receptors acting on atrioventricular conduction (β 
stimulation) and repolarisation. Myocardial ischaemia can result when there is an imbalance 
in the oxygen supply and demand with coronary vasoconstriction. (32, 67) 
In a study by McLeod et al (59) it was found that  with a slow IV injection of 5 U of oxytocin 
there was a temporary change in cardiac index and increased heart rate, but the blood 
pressure remained unchanged. An additional IV infusion of oxytocin did not adversely affect 
maternal hemodynamics.  
A single double blinded study by Thomas et al (68) compared the effects of 5 U of oxytocin 
when given as an IV bolus or as an infusion over 5 min in 30 women undergoing elective 
caesarean section. The study measured heart rate (HR), mean arterial blood pressure 
(MAP) and estimated blood loss between the two groups.  
In the bolus group HR increased by 17 beats/min compared to 10 beats/min in the infusion 
group. MAP decreased by 27 mmHg in the bolus group and a steady decline by 8 mmHg 
was noted in the infusion group. There was no difference in the estimated blood loss. (68) 
Pulmonary artery  pressures are markedly increased for at least 10 minutes following a bolus 
of 10 U of oxytocin during general anaesthesia, in patients with severe pre-eclampsia similar 
effects were seen at a much lower bolus dosage of 2,5 U (5). 
According to the Report on Confidential Enquiries into Maternal Deaths in South Africa of 
2004-2007 at least one patient suffered a fatal cardiac arrest after a 10 U bolus of oxytocin 
IV was administered during emergency caesarean section (5). 
2.5.2 Headache and Flushing 
A rapid fall in mean arterial pressure may cause a decrease in cerebral perfusion pressure, 
which often causes headaches and flushing in patients, especially when hypovolaemic. This 
could stimulate nausea and vomiting that could lead to aspiration and other complications in 
the pregnant patient. (5) 
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2.5.3 Water Intoxication and Hyponatremia 
Due to structural similarity with vasopressin (an antidiuretic hormone), an overdose of 
oxytocin may also cause water retention, hyponatremia, pulmonary oedema, seizures and 
coma (5, 27, 61, 62). 
Water Intoxication associated with oxytocin infusion was first reported by Liggins in 1962 
(27, 62). It was found that the antidiuretic effect was dose dependant, and a study by Ahmad 
et al (27) showed that oxytocin caused a marked decrease in the free water clearance. 
There is little evidence to determine an optimal rate of infusion following an initial bolus or 
slow iv administration of oxytocin, but oxytocin is much less active as an antidiuretic when 
the infusion rate is less than 45 milliunits/min (5). 
2.5.4 Foetal Adverse Effects 
One of the greatest dangers of an oxytocin infusion is umbilical vasoconstriction leading to 
foetal hypoxia and even uterine rupture. A decreased blood flow to the foetus could result in 
a lowered oxygenated arterial blood (SaO₂) in the foetus, seizures, and even retinal 
haemorrhages. (67) 
A study in Asia showed that oxytocin was readily administered in third stage of labour to 
prevent  PPH, but often guidelines for usage were not applied and maternal and foetal 
outcomes were often poor, with a high incidence of uterine rupture and/or foetal asphyxia 
(36). 
2.6 Knowledge 
Firstly knowledge in general of drugs will be discussed followed by doctor’s knowledge of 
oxytocin. 
Knowledge of physicians seem to be varied and often lacking in regards to drug 
administration, costs of drugs,  pharmacokinetics and pharmacodynamics of drugs 
prescribed (19, 24-26). 
 
A study done in Spain by Garcia et al (24) analyzed 1220 physicians’ knowledge on generic 
drugs through a questionnaire, as well as attitudes and professional competence with 
regards to prescribing these drugs. It was found that physicians’ knowledge was inadequate 
and that Spanish health authorities should offer better training and information about generic 
drugs to physicians (24).   
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In Pakistan a cross-sectional study on 131 general practitioners showed that knowledge 
regarding the major therapeutic use and adverse effects of drugs prescribed was deficient 
amongst all practitioners. Three commonly prescribed drugs were selected from a list of 
drugs approved by the Ministry of Health in Pakistan, and a multiple choice questionnaire 
distributed amongst general practitioners. A statistically significant (p < 0.01) lack of 
knowledge was identified amongst almost 61% of all respondents. (25) 
Another study assessing primary health care physicians’ knowledge, attitude and practise in 
the management of osteoporosis in the Al-Jouf province of Saudia Arabia, found that with a 
response rate of 85% (77/90 questionnaires were returned) most physicians lacked 
knowledge on the management of osteoporosis. Appropriate attitudes were identified 
amongst responders but practise regarding the disorder appeared inappropriate. (26) 
 
Rowe et al (69) demonstrated that doctors’ knowledge on drug costs was absolutely 
deficient in a study where 50 doctors working in the National Health Service in England 
completed  a questionnaire on the cost of 15 commonly prescribed medications. 
   
Internationally guidelines and protocols exist in the management of certain medical 
disorders, but often physicians do not follow guidelines. Physician adherence to guidelines is 
critical to the improvement of outcomes in patients, but following a guideline without 
adequate knowledge of the drug has also proven to be disastrous to patient outcomes.(23, 
34, 45-47) 
 
A multicentre study conducted in maternity hospitals in Ecuador, El Salvador, Mexico and 
Uruguay showed that the knowledge of the health providers in regard to giving 
corticosteroids in preterm labour to prevent risk of respiratory distress syndrome, 
intraventricular hemorrhage, and neonatal mortality was lacking. Very few health care 
providers (midwives and physicians) used the recommended regimens. Of the total of 353 
healthcare providers, between 11% and 35% responded that their knowledge on the 
administration of corticosteroids was poor, and in only one country 90% of the responders 
were following the recommended regimen. (16) 
 
A study in Karnataka, India in-depth interviews were conducted on 140 health care providers 
which included, physicians, nurses, traditional midwives and unlicensed village/traditional 
doctors, it was found that oxytocin administrative practises were varied and most responders 
had little knowledge of adverse effects. Several of the village doctors also insisted that there 
were no adverse effects, and had never encountered obstetric complications while attending 
deliveries. (17) 
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Through this study, physicians and a few village doctors expressed the belief that there was 
a rampant misuse of uterotonics by unqualified, poorly-knowledgeable health care providers 
in the community. Nurses also reported that family members insisted on the usage of 
uterotonic drugs during labour without being aware of potential adverse effects of excessive 
usage. This study concluded that communication needed to improve between community 
members and health care providers regarding uterotonic usage and training and other 
interventions were needed to address identified gaps in knowledge by health care providers 
as well as up to date information on appropriate uterotonic usage and adverse effects. (17) 
 
Another study done in India’s most populous state, Uttar Pradesh, showed that there was 
uterotonic agent misusage in labour augmentation in both institutional and community 
deliveries. This was partially due to uterotonics being widely available, the perception that 
uterotonics were curative agents, and the lack of knowledge of the health care provider 
administering the drug during delivery. This study also showed that financial incentive played 
a role in the misusage of oxytocin during delivery, often leading to higher dosages being 
administered with more adverse effects. (18) 
 
“A private doctor may give one or two injections of Syntocinon® (synthetic oxytocin) for the 
money, but in government hospital a limited amount is given”- Village Doctor, 
 Gorakhpur. (18) 
 
The administration of any drug thus may be dangerous if given by a health care provider 
without the adequate knowledge regarding the adverse effects, dosage and administration of 
that particular drug. Up to date information is essential for safe practise by any health care 
provider, ranging from physicians, traditional doctors, midwives, nurses and any other 
practitioner prescribing and administering medication to a patient. 
 
Even with the knowledge that a bolus of 10 U IV oxytocin caused a maternal death in the 
UK, Bolton et al (19) showed that  23% of physicians still did not change their clinical 
practise of administering a 10 U bolus. 
 
Irrespective of the fact that guidelines and protocols exist, change in clinical practise is not 
guaranteed. The implementation of knowledge is therefore the responsibility of the health 
care provider themselves. (19, 45) 
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Doctors’ in general seem to have variable knowledge of drugs they prescribe and administer 
to patients (15-19, 24, 26). Jansen et al  (14) is of the opinion that doctors should have a 
comprehensive knowledge of medication they prescribe and administer to patients as these 
are essential to a doctors’ daily practise. No doctor should be allowed to prescribe or 
administer medication if they do not have up-to-date knowledge of that medication. 
2.7 Summary 
In this chapter PPH and the management, and usage of oxytocin was discussed. Knowledge 
of drugs in general and oxytocin was reviewed. In Chapter Three the research methodology 
will be discussed. 
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CHAPTER THREE 
RESEARCH METHODOLOGY 
3.1 Introduction 
In this chapter the problem statement, aim and objectives, ethical considerations, research 
methodology and validity and reliability will be discussed in detail. 
3.2 Problem Statement 
Syntocinon® is a dangerous drug with a narrow therapeutic range in terms of maternal 
morbidity (3, 5, 11). Legally doctors should have comprehensive and up-to-date knowledge 
of medication that they prescribe and administer (14). 
 No specific protocol has been adopted at the Department of Anaesthesiology of the 
University of the Witwatersrand (Wits) for the administration of Syntocinon®.  Current 
knowledge and practises regarding Syntocinon® amongst Wits anaesthetists was unknown.  
3.3. Aim 
The aim of the study was to describe the current knowledge and practise of the 
anaesthetists in the Department of Anaesthesiology at Wits regarding Syntocinon® during 
caesarean section under spinal anaesthesia. 
3.4 Objectives 
The primary objectives of this study were to: 
 describe the anaethetists’ knowledge of Syntocinon® 
 describe anaethestists’ practise regarding Syntocinon®. 
The secondary objectives were to: 
 describe the difference in knowledge between the medical officers, junior registrars, 
senior registrars and consultants 
 compare the knowledge between the junior doctors and the senior doctors. 
3.5 Ethical considerations 
Approval to conduct this study was obtained from the Postgraduate Committee (Appendix 1) 
and the Human Research Ethics Committee (Medical) (Appendix 2) of the University of the 
Witwatersrand. 
An information letter (Appendix 1) was provided to the participants explaining the purpose 
and process of the study.  
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Consent was implied by completing the questionnaire (Appendix 2). To limit data 
contamination, the researcher was present during the completion of every questionnaire. 
The researcher aimed to ensure anonymity and confidentiality by requesting that all 
participants fold and place completed questionnaires in a sealed, closed collection box. By 
being present during the completion of the questionnaire the researcher ensured that no 
data contamination could take place between participants in a meeting. Data will be stored 
securely for six years following completion of the study.  
This study was conducted according to the South African Good Clinical Practice Guidelines 
(20) and the Declaration of Helsinki (21). 
3.6 Research Methodology 
3.6.1 Research design 
A descriptive, prospective, contextual study design was used. 
 
A descriptive study describes data and characteristics about the population or phenomenon 
being studied. The data description is factual, accurate and systematic. The variables cannot 
be manipulated by the researcher. (70) This study describes the knowledge and practice of 
anaesthetists regarding Syntocinon®. 
 
A prospective study is a study design where the variables are measured during the time the 
study is taking place. (70) By using a questionnaire in this study the variables were 
measured during the time the study took place. 
 
This study described the level of knowledge and practise regarding Syntocinon ®amongst 
the anaesthetists working in the Department of Anaesthesiology at Wits, and will be deemed 
contextual as it took place in a specific location or area. (71) 
3.6.2 Study population 
The study population consisted of the anaesthetists working in the Department of 
Anaesthesiology at Wits. 
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3.6.3 Study sample 
3.6.3.1 Sample size 
At the time that the study was conducted it was estimated that there were 228 anaesthetists 
working in the department. A biostatistician was consulted, and it was determined that if the 
power of the study was chosen to be 80% (using EpiInfoTM version 6), a sample size of 116 
respondents was needed. 
3.6.3.2 Sample method 
A convenience sampling method was used. The questionnaire was presented at academic 
departmental meeting at each of the four individual hospitals, CHBAH, CMJAH, RMMCH 
and HJH. Doctors attending these meetings were approached for inclusion in the study. 
They were requested to only complete the questionnaire once.  
3.6.3.3 Inclusion and exclusion criteria 
Inclusion criteria and exclusion criteria for study were defined. 
An inclusion criterion for this study was all anaesthetists attending the academic 
departmental meetings and those willing to participate in the study. Incomplete 
questionnaires were included and questions not complete were taken as incorrect. 
An exclusion criterion was defined as questionnaires where individuals could be identified. 
3.6.4 Data collection 
3.6.4.1 Development of questionnaire 
No questionnaires assessing the appropriate administration of Syntocinon® were identified. 
A draft questionnaire based on a review of the literature was developed by the researcher 
with guidance from the co-supervisor, who is a specialist in the field of anaesthesiology and 
pharmacology and the supervisor who has a special interest in obstetric anaesthesiology.  
The questionnaire underwent validation as follows: 
- It was evaluated by four specialist anaesthesiologists who have an interest in 
obstetric anaesthesia and who are affiliated with Wits. 
- It was then evaluated by a professor of anaesthesiology who has a special interest in 
obstetric anaesthesiology, has undertaken research and published articles regarding 
Syntocinon® in obstetric usage in anaesthesia, and is also the head of the Obstetric 
Anaesthesia Special Interest Society (OASIS), a special interest group affiliated with 
the South African Society of Anaesthesiologists (SASA). 
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- It was then re-evaluated by specialist anaesthesiologists, and professor emeritus 
affiliated with Wits who has an interest in obstetric anaesthesiology and 
pharmacology, who has published a textbook regarding pharmacology application in 
anaesthesiology.  
The self-administered questionnaire (Appendix 2) consisted of three sections.  
Section 1 requested demographic data (questions 1 to 3) 
      • gender.  
 years of experience in anaesthesiology 
 professional designation e.g. registrar, consultant, medical officer 
 
Section 2 consisted on knowledge questions (questions 4 to 9) 
 side effects related to Syntocinon® 
 drug receptors and pharmacokinetics of Syntocinon®. 
 
Section 3 addressed current practise regarding Syntocinon®. (questions 10 to 12) 
 dosage 
 frequency 
 rate 
 method. 
 
3.6.4.2 Data collection process 
Data was collected at random academic departmental meetings until the sample size has 
been realised. Participants were requested to only complete one questionnaire and refrain 
from completing questionnaires at each meeting. The researcher was present during 
completion of questionnaires to assist with possible queries and prevent data contamination. 
Before distribution of questionnaires they were numbered in order to keep track of completed 
questionnaires and to calculate a response rate. 
 
Information letter (Appendix 1) and questionnaires (Appendix 2) were distributed following a 
brief introduction to the study. Anaesthetists were requested to return questionnaires, 
whether completed or not, in a sealed marked “Return Questionnaire” box. 
3.6.5 Data analysis 
A Microsoft ® Office Excel spreadsheet was used to capture the data. Data was analyzed 
using STATISTICA version 11. Descriptive and inferential statistics were used. 
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3.7 Validity and reliability 
Validity of a study shows whether the conclusions of the study are justified based on the 
design and interpretation (72). Validity of an instrument is defined as its accuracy to perform 
the intended measurement. (71) 
Reliability is associated with the consistency of the measurement technique. (71) 
The validity and reliability of this study was ensured by: 
 an appropriate study design and data gathering techniques 
 a representative sample size determined by a biostatician 
 the study population and sample was close to the same size 
 selection bias was minimized by approaching all doctors in the department 
 the researcher being the only data collector and that the same information is given to 
all participants, and therefore by being present ensured that no data contamination 
occurs 
 all questionnaires being collected, completed or uncompleted, in a sealed box 
marked “return questionnaires” 
 data analysis techniques being decided upon in consultation with a biostatician. 
3.8 Summary 
In Chapter Three the problem statement, aim, objectives, ethical considerations, research 
methodology and the validity and reliability of this study were presented. In the following 
chapter, Chapter Four the results are presented and discussed.  
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CHAPTER FOUR 
                                            RESULTS AND DISCUSSION 
4.1 Introduction 
The results of the study according to the primary and secondary objectives, as well as the 
discussion are presented in this chapter.  
The primary objectives of this study were to: 
 describe the anaethetists’ knowledge of Syntocinon® 
 describe anaethestists’ practise regarding Syntocinon®. 
The secondary objectives were to: 
 describe the difference in knowledge between the medical officers, junior registrars, 
senior registrars and consultants 
 compare the knowledge between the junior doctors and the senior doctors. 
4.1.1 Sample realisation 
A total of 121 questionnaires were distributed between the four hospitals during the period 
14 to 28 April 2015. Two questionnaires were excluded as they were returned blank and one 
was excluded as participant was identified from questionnaire and anonymity was not 
maintained. Therefore a total of 118 were included in the statistical analysis (n=118) with a 
response rate of 98%. 
4.2 Results 
The findings have been described and analysed using descriptive and inferential statistics. 
All percentages are rounded to whole numbers. Where a question had more than one 
correct answer each correct answer was allocated one point. Thus, the knowledge section of 
the questionnaire totalled to 15. Adequate knowledge was described as attaining an average 
of 80% or more.  
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4.2.1 Demographics 
The gender, years of anaesthesiology experience and professional designation of the 
participants are shown in Table 4.1. 
Table 4.1 Demographics of participants 
Demographics Number (n) Percentage (%) 
Gender   
  Male 56 47 
 Female 62 53 
Years of anaesthesiology experience   
 0-4 years 47 40 
 4-8 years 46 38 
 More than 8 years 25 22 
Professional designation in anaesthesiology 
department 
  
 Medical Officer 28 24 
 Junior Registrar 35 30 
 Senior Registrar 21 18 
 Consultant 34 29 
 
4.2.2. Primary objective: to describe the anaesthetists’ knowledge of 
Syntocinon® 
None of the 118 participants answered all the knowledge questions correctly. Only 10 (8%) 
participants received a score ≥ 80%.The mean (SD) score attained for the knowledge 
questions was 59% (12.11). The number and percentage of correct, incorrect and 
unanswered questions are shown in Table 4.2.Only 6 (5%) participants correctly identified all 
six risk factors. 
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Table 4.2 Results of knowledge test 
Question and description Correct  
n (%) 
Incorrect 
n (%) 
Unanswered 
n (%) 
4. What are the most 5 most common side effects of 
Syntocinon® administration IV?   
   Hypotension                                                 
   Nausea 
   Headache 
   CNS side effects 
   Bradycardia  
 
 
112 (95) 
91 (77) 
67 (57) 
46 (39) 
41 (35) 
 
 
6 (5) 
27 (23) 
51 (43) 
72 (61) 
77 (65) 
 
 
0 
0 
0 
0 
0 
5. Where are the receptors for Syntocinon found? 8 (7) 
 
 
 
110 (92) 
 
 
 
0 
 
 
 
6. What are the risk factors for developing post-partum  
 Haemorrhage (PPH)? 
    Multiparity 
    Trauma of the genital tract 
    Retained products of conception 
    Coagulation abnormalities 
    Uterotonic drugs 
    Uterine atony 
 
 
82 (69) 
71 (60) 
94 (80) 
93 (78) 
42 (36) 
114 (97) 
 
 
36 (31) 
47 (40) 
24 (20) 
25 (22) 
76 (64) 
4 (3) 
 
 
0 
0 
0 
0 
0 
0 
7. Who is the well published South African expert? 41 (35) 
 
 
 
70 (59) 
 
 
 
7 (6) 
 
 
 
 
8. What is the first line agent in the management of 
hypotension? 
 
19 (16) 
 
99 (84) 
 
0 
9. What agent is an oxytocin antagonist? 32 (27) 76 (65) 10 (8) 
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4.2.3 Primary objective:  to describe anaethestists’ practise regarding 
Syntocinon® 
The practise regarding the usage of drugs is often varied according to the knowledge and 
experience of the user, and when no protocol is in place at an institution regarding the 
dosage and indication when to use a drug in question, practice varies and may even be 
incorrect. The practice of anaesthetists regarding Syntocinon® IV administration is shown in 
Table 4.3.  
Table 4.3 Practice of anaesthetists regarding Syntocinon® IV administration  
Question and description  Number and percentage 
n (%) 
10. What dose of Syntocinon® IV do you use in an 
uncomplicated caesarean section under spinal 
anaesthesia? 
Bolus 2U IV only 
2U Bolus IV with 8 U in 1 litre Ringers Lactate at 125ml/hr 
5 U Bolus IV only 
10 U Bolus IV only 
10 U in IV infusion of 1 litre Ringers lactate at a rate of 
125ml/hr 
2U IV Bolus with 20 U in 1 litre Ringers Lactate at a slow 
rate/ 125ml/hr IVI 
 
 
 
 
29 (25) 
40 (34) 
8 (7) 
8 (7) 
 
14 (12) 
 
19 (16) 
11. Do you use Syntocinon® IV (bolus or infusion) during 
Caesarean section under spinal anaesthesia? 
Yes with every caesarean section 
Yes but only when surgeon indicates it 
No but use other uterotonic drugs instead 
No never use it 
 
 
 
109 (93) 
6 (5) 
0 
3 (2) 
 
12. How do you administer Syntocinon® IV? 
Bolus only 
Infusion only 
Bolus and infusion 
 
22 (19) 
18 (15) 
78 (66) 
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4.2.4 Secondary objective: to describe the difference in knowledge between 
the medical officers, junior registrars, senior registrars and consultants 
The scores obtained for the knowledge test, by professional designation, are shown in 
Figure 4.1.  
 
Figure 4.1. A graphic representation of comparison of knowledge of participants according to 
designation. 
4.2.5 Secondary objectives: to compare the knowledge of junior and senior 
doctors in the anaesthesiology department. 
Of the 118 participants, 63 (53%) were junior doctors and 55 (47%) were senior doctors. The 
junior doctors obtained a mean (SD) score of 60.1% (11.5) and the senior doctors 57.3% 
(12.7). The mean difference between the scores was -2.8% (95% CI -7.2:1.6) which was not 
statistically significant (p = 0.2).  
4.3 Summary 
The results of this study have been presented in this chapter and discussed as per the 
research objectives. Descriptive and inferential statistics were used in the analysis of these 
findings. In Chapter 5 the summary limitations, recommendations and conclusion are 
discussed. 
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CHAPTER FIVE 
DISCUSSION 
5.1 Introduction 
In Chapter 5, the results and limitations of this study will be discussed in detail. 
5.2 Sample Realization 
At the time the survey was conducted it was estimated that there were 228 anaesthetists 
working in the department at Wits. With the assistance of a biostatistician it was determined 
that to achieve a power of 80% it would be necessary to obtain a sample size of 116 
participants. As only 8% of participants obtained a score ≥ 80%, for the knowledge section of 
the questionnaires, the original calculated sample size may be insufficient. 
A total of 121 questionnaires were distributed during the chosen collection period (April 
2015), 120 were returned but only 118 were included in the statistical analysis as 2 
questionnaires were found to have participant identifiers in the responses. Although the 
response rate for the survey was 98%, 118 participants represents only 52% of the 
department at Wits at the time the study was conducted. 
Using Raosoft® survey sample calculator, if the population size is 228, the response 
distribution 50%, confidence level 95% and margin of error 5% the recommended sample 
size is 144 participants.  
As the researcher was only able to distribute 121 questionnaires during the data collection 
period, an insufficient number of participants may have been enrolled as level of knowledge 
was found to be poorer than expected when the study was designed. 
5.3 Data Contamination 
As the researcher conducted the survey at 4 separate academic departmental meetings in 
order to obtain the necessary sample size, there is a possibility that data contamination 
could have occurred. It would have been preferable to complete the study on a specific day 
at a specific time, but due to the nature of the meetings during the period of data collection 
as well as poor attendance of academic meetings, this was unavoidable. However, the levels 
of knowledge were still poor and therefore the possibility that data contamination could have 
occurred has not affected the outcome and recommendations of the study. 
5.4 Demographics 
Unfortunately, when the questionnaire was designed an error was made in defining years of 
anaesthesiology experience. Categories of 0-4 years, 4-8 years and > 8 years were options 
available in the questionnaire, however these categories overlap, and should rather have 
been 0-4 years, 5-8 years and >8 years experience. This may have lead to participants 
misclassifying themselves. However, the researcher did not describe knowledge according 
to years of experience but if the questionnaire were to be used in any future studies the 
researcher recommends that this be addressed. 
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Although the definition of junior registrar and senior registrar was included in the research 
methodology it was not defined for participants on the questionnaire and participants were 
therefore allowed to self categorize. This may have lead to a misclassification of registrars 
and therefore the scores obtained for the knowledge test, by professional designation, may 
be misrepresentative and rather an overall percentage for registrars should have been 
described. If the questionnaire were to be used in any future studies the researcher 
recommends that the categories of Junior and Senior registrars be defined for participants 
on the questionnaire. 
5.5 Knowledge Results 
The results of this section are similar to other international studies conducted by Rowe et al 
(69) and Garcia et al (6), that showed in Spain and England knowledge of doctors were 
deficient when using drugs that are commonly prescribed, such as Syntocinon® IV for 
caesarean section.  
Although only 8% (10) participants obtained adequate knowledge scores as defined as a 
score of > 80%, the three most common side effects were well identified, yet CNS side 
effects and bradycardia were poorly recognised. The question relating to the physiology of 
Syntocinon® was also poorly answered. The lack of knowledge in these areas needs to be 
addressed in future departmental education programmes.  
Although participants scored well in identifying 5 of the 6 risk factors for PPH, the remaining 
risk factor (uterotonic drugs) was poorly identified with only 42% correctly identifying it as a 
risk factor for PPH. This may be due to the fact that the option presented may have been 
ambiguous for participants and that the option available should rather have been presented 
as inadequate usage of uterotonic drugs or absence of usage of uterotonic drugs. If the 
questionnaire is to be be used in future studies, the researcher recommends that this options 
(uterotonic drugs) be more clearly defined for participants. 
At the time the study was designed an article regarding the usage of Syntocinon® was 
published in the South African Journal of Anaesthesia and Analgesia (SAJAA) volume 20, 
number 1 (2014), ‘New trends in the management of post partum hemorrhage’, the first 
author of this article was Professor Rob Dyer. Question 7 of the questionnaire, (who is the 
well published South African expert on Syntocinon®) was designed to indirectly assess if 
participants had read or knew about this recently published article. The fact that only 41% of 
participants correctly identified Professor Dyer as the South African expert, suggests that 
participants may not have up to date knowledge on this topic, or may not be accessing the 
SAJAA. The researcher recommends that studies regarding readership of the SAJAA and 
access to information in the SAJAA be performed. 
 
Marike De Jager      Student Number: 737758     October 2016 
 
Page 34 
 
The use of fluid as a first line agent in the management of hypotension was poorly answered 
with only 16% of participants answering correctly. This question was designed as an open 
ended question, and if the questionnaire were to be used in future studies perhaps offering 
options to participants may result in higher scores for this question. 
The agent that is an oxytocin antagonist was poorly identified with only 27% of participants 
correctly identifying the drug. This needs to be addressed in future departmental education 
programmes. 
The study showed that medical officers scored better than registrars, who in turn scored 
better than consultants in the knowledge section. This is in keeping with the fact that in the 
Wits anaesthesiology department, medical officers and junior registrars are most often 
assigned to the obstetric theatres. However, even in these groups the knowledge scores 
were poor and thus future education programmes should target all professional 
designations.  
5.6 Practice of anaesthetists regarding Syntocinon® administration 
Even with the knowledge that a bolus of 10 U IV oxytocin caused a maternal death in the 
UK, Bolton et al (19) showed that  23% of physicians still did not change their clinical 
practise of administering a 10 U bolus. As seen in our study at least 7% of participants 
administered a 10 U bolus IV of Syntocinon® with the knowledge that the latter drug has 
many side effects as seen from question 10 in the questionnaire (Appendix 2). 
In a study by Bhattacharya et al (32) it was found that a significant number of cardiovascular 
events occurred with a bolus regimen of the oxytocin in comparison with an infusion. As 
shown in this study 19% of participants are still administering Syntocinon® IV as a bolus and 
this could contribute to significant maternal morbidity, and standardized protocols need to be 
urgently implemented to avoid adverse outcomes. 
As shown in this study, the practice of anaesthetists at Wits also varied when it came to 
dosage and usage of Syntocinon® IV and even though international guidelines exist with 
recommended practice, no standardized practice has been adopted at Wits. This too, needs 
to be urgently addressed. 
Of the 118 participants, 2% of participants reported that they never used Syntocinon® IV. 
The lack of usage of Syntocinon® IV could have a significant impact on maternal morbidity 
and mortality and significantly increases the risk of PPH.(5) This needs to be urgently 
addressed. 
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The World Federation of Societies of Anaesthesiologists (WFSA) guideline recommends a 
slow IV bolus of 5 U that can be repeated if needed, thereafter an infusion can be 
commenced using 10 U/hr for 4 hours. (49) SASA has no guidelines specific to use of 
oxytocin in uncomplicated caesarean section. (46)The Royal College of Obstetricians and 
Gynaecologists (RCOG) and National Institute of Clinical Excellence (NICE) recommends 
the use of a bolus of 5 U oxytocin by slow IV injection with the option of repeated dosages. If 
further uterine atony continuous an oxytocin infusion of 40 U in 500 ml Hartmann’s solution 
at a rate of 125 ml/hour is recommended. (21,28) The American Society of Obstetricians and 
Gynaecologists also has a guideline which recommends 20 U in 500 ml Ringer’s lactate at 
125 ml/hour.(37) Only 66% of participants in this study stated that they use a bolus and 
infusion technique. This suggests that participants may not be aware of international 
guidelines and highlights the lack of standardized practice at Wits. Urgent protocols 
regarding Syntocinon® IV usage needs to be instituted and a standardised practice needs to 
be adopted in the Wits anaesthesia department. 
5.7 Summary 
In this chapter the results of the study were discussed. This study has highlighted that there 
is no current standardised practice at Wits and that knowledge of Syntocinon® in the Wits 
anaesthesia department is poor. A standardised protocol needs to be urgently implemented 
and adopted and ongoing departmental education needs to be instituted to prevent adverse 
maternal outcomes. 
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CHAPTER SIX 
SUMMARY, LIMITATIONS, RECOMMENDATIONS AND THE CONCLUSION 
6.1 Introduction 
In this chapter a summary of the study, the limitations, recommendations for clinical practice 
and further research and a conclusion are presented.   
 
6.2 Summary of the study  
 
6.2.1 The aim of the study 
The aim of the study was to describe the current knowledge and practise of the 
anaesthetists in the Department of Anaesthesiology at Wits regarding Syntocinon® during 
caesarean section under spinal anaesthesia. 
6.2.2 Objectives of the study 
The primary objectives of this study were to: 
 describe the anaethetists’ knowledge of Syntocinon® 
 describe anaethestists’ practise regarding Syntocinon®. 
The secondary objectives were to: 
 describe the difference in knowledge between the medical officers, junior registrars, 
senior registrars and consultants 
 compare the knowledge between the junior doctors and the senior doctors. 
6.3 Summary of the methodology used in the study 
A descriptive, prospective, contextual study design was used. A convenience sampling 
method was used in this study. The study population consisted of 118 anaesthetists working 
in the Department of Anaesthesiology at Wits. The questionnaire was presented at random 
academic departmental meetings at each of the four individual hospitals. A self-administered 
questionnaire (Appendix 2) with a demographics section, knowledge section and a practice 
section was used to collect data. 
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The first three questions were demographic related questions. The next six questions 
(question 4 to 9) tested the participants’ knowledge on side effects, pharmacology, and 
physiology of Syntocinon®. The practice section was divided into 3 questions (question 10 to 
12) concerning the administration of Syntocinon®. 
The anaesthetists were approached at work during the various departmental meetings and 
informed of the study purpose via an information letter (Appendix 1) and via the researcher. 
It was explained that the participant’s identity would remain confidential and that there would 
be no consequence to participating or declining to participate in the study. A questionnaire 
(Appendix 2) was given to anaesthetists consenting to participate in the study. 
The questionnaire was personally distributed to the anaesthetists by the researcher. The 
researcher was present during the completion of the questionnaire to prevent contamination 
of information. Once completed, the questionnaire was inserted back into a sealed collection 
box by the researcher. Blank questionnaires were excluded from the study and those that 
had questions that were unanswered were taken as incorrect answers. 121 questionnaires 
were initially handed out and two were returned blank, and one had a participant’s name on 
it, these three were not included in the analysis of the questionnaires, thus 118 
questionnaires were included in the study. 
6.4 Results 
The demographic section consisted of three questions and results showed that 
approximately half of the participants were female 62 (53%). Of the participants 47 (40%) 
had between 0-4 years of experience, 46 (38%) 4-8 years of experience and 25 (22%) had 
more than 8 years of experience. 
 
Only 10 (8%) anaesthetists had adequate knowledge (more than 80% correct answers in the 
questionnaire).Thus the primary objective to describe anaesthetist’s knowledge of 
Syntocinon® showed an inadequate knowledge in general between all designations of 
anaesthetists after completion of the questionnaire (Appendix 4). 
 
The second primary objective was to describe the anaesthetists practice with regards to 
Syntocinon® and the outcome of the questionnaire showed that practice varied amongst 
anaesthetists and individual’s practice was not standardised according to a protocol.  
 
109(93%) participants used Syntocinon. 
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 The knowledge section of the questionnaire showed an inadequate knowledge in general 
between all designations of anaesthetists. ® IV with every caesarean section and 6(5%) 
participants only administered Syntocinon® IV at the surgeons’ request, whilst 3(2%) 
participants never gave Syntocinon® IV .Of the 115(98%) participants who did administer 
Syntocinon® IV the practice varied with regards to dosage and bolus of Syntocinon® IV only 
and combining a bolus of Syntocinon® IV with IV fluid.  
 
The secondary objectives were to describe the difference in knowledge between the medical 
officers, junior registrars, senior registrars and consultants. The mean score amongst all 
participants was found to be 59% and medical officers scored the highest with scores of 62% 
followed by senior registrars who scored 60%, junior registrars scoring 59% and the 
consultants scoring 55%.  
 
Of the 118 participants there were a total of 63 junior doctors and 55 senior doctors. The 
junior doctors obtained a mean score of 60% compared to the senior doctors who obtained a 
mean score of 57% thus comparing the knowledge between the two designations. 
 
6.5 Limitations 
This study was done contextually in the Department of Anaesthesiology at Wits. Therefore, 
the results may not reflect the knowledge and practices of any other anaesthetists in the 
anaesthetic community or in other departments. 
Convenience sampling was used and thus only the knowledge and practice of those present 
at the academic departmental meetings was assessed and therefore this study may not 
reflect the knowledge and practice of the whole department via either over or under 
representation. 
Sample size may not be representative of the whole department as only 52% of the 
department completed the questionnaire. 
As the survey was conducted at 4 seperate academic departmental meetings, data 
contamination may have occurred.  
.  
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6.6 Recommendations for clinical practice 
6.6.1 Educational Lecture and email 
An educational presentation on Syntocinon® will be given at a combined academic 
departmental meeting and a follow up email sent to the entire Department of 
Anaesthesiology at Wits to ensure that all anaesthetists’ knowledge and practice is 
improved. 
The outcome of our study showed inadequate knowledge and varied practice in regards to 
the administration of Syntocinon® in the Department of Anaesthesiology at Wits. 
Doctors should also be encouraged to read more recently published articles on IV 
Syntocinon® as the use of this drug has recently changed. Articles relevant to this topic 
could be distributed to the department via email. 
 
6.6.2 Guideline and Protocol for Department 
A protocol for dosing of Syntocinon® in an uncomplicated caesarean section under spinal 
anaesthesia should be developed and implemented so that standardised dosing occurs 
amongst all designations of anaesthetists at the Department of Anaesthesiology of Wits. 
These guidelines should be distributed amongst the staff and should be clearly displayed as 
a poster in obstetric theatres. 
 
Guideline posters based on the Essential Steps to the Management of Obstetric 
emergencies’ (ESMOE) recommendations for management of caesarean section 
emergencies such as PPH should be strategically placed in the labour ward where the 
doctors and nursing staff can view them frequently and easily. 
6.7 Recommendations for further research 
a) A follow up study is needed to evaluate the efficacy of the educational programmes put in 
place to improve the knowledge of the anaesthesiologists at Wits.  
b)This study should also be repeated in other Departments of Anaesthesiology across the 
country as anaesthetists elsewhere may also have a poor knowledge and understanding of 
Syntocinon®. 
c) Research regarding readership of SAJAA is recommended. 
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6.8 Conclusion 
An inadequate level of knowledge and the varying practice with regards to the administration 
of Syntocinon® amongst anaesthetists in the Department of Anaesthesiology at Wits was 
found. Further education in regards to practice and general knowledge are necessary to 
improve patient outcomes and reduce mortality rates. 
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Appendix One: Participant information letter 
Dear Colleague. 
Hello, my name is Marike De Jager. I am an anaesthesiology registrar in the Department of 
Anaesthesiology at Wits. 
I would like to invite you to participate in a research study titled: “Current knowledge and 
practise regarding Syntocinon® for caesarean sections in a department of anaesthesiology”. 
This study will contribute towards the fulfilment of my MMed degree in the Faculty of Health 
Sciences at the University of Witwatersrand. 
The aim of the study will be to determine current knowledge and practise regarding 
Syntocinon® of anaesthetists at Wits. Syntocinon® is a dangerous drug and adequate up-to-
date information is necessary to ensure safe practise. This will be assessed using a self-
administered questionnaire. 
The study has been approved by the Human Research Ethics Committee (HREC) and the 
Postgraduate Committee of the University of the Witwatersrand.  
Taking part in this study may also assist in determining how the department can improve 
teaching and may possibly lead to the development and implementation of a formal 
Syntocinon® protocol. 
The questionnaire which includes both multiple choice questions as well as open-ended 
questions will take approximately 10 minutes to complete. The questionnaire completed or 
uncompleted should be placed into the unmarked envelope supplied and sealed. The 
information will be anonymous as your name will not appear on the questionnaire. It will also 
be confidential as only my supervisors and I will have access to the completed 
questionnaires. 
Participation in this study is voluntary and if you decide not to participate no penalty will be 
incurred.  
Before completion of this questionnaire, please ensure that you understand the above 
information. If you have any questions regarding this study please contact: Professor 
Cleaton-Jones (chairperson of the HREC) 011 717 1234 or myself, Marike de Jager  
082 825 1218. 
Thank you for taking the time to read this letter and being willing to participate in the study.                                                                      
Yours sincerely, Marike de Jager                                                        
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Appendix Two 
Questionnaire: 
Please complete/and or circle the most appropriate answer for the following questions: 
1. Please specify Gender: 
                 Male                    Female 
 
2. Years of Anaesthesiology Experience: 
 0 – 4 years 4 – 8 years More than 8 years 
 
3. Position in Anaesthesiology Department at WITS: 
Medical Officer Junior Registrar Senior Registrar Consultant 
   
4. What are the most 5 most common side effects of Syntocinon® administration IV? 
Please tick appropriate boxes 
  
5.  Where are the receptors for Syntocinon® found: 
_____________________________________________________________________ 
6. What are the risk factors for developing post-partum haemorrhage (PPH)? 
 
Nausea Headache Hypotension Myocardial 
Ischemia 
Shivering Water Intoxication QT lengthening on 
ECG 
Bleeding 
Tendencies 
Bradycardia CNS side effects Cardiac Arrest Visual Disturbance 
Multiparity Advanced 
maternal age 
Retained 
products of 
conception 
Primigravida Twin 
Pregnancy 
Trauma of the 
genital tract 
Coagulation 
abnormalities 
In-vitro 
Fertilisation 
(IVF) 
Uterotonic 
Drugs 
Uterine Atony 
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7. Who is the well published South African expert regarding Syntocinon®? 
_________________________________________________________________________
_________________________________________________________________________ 
8. What is the first line agent in the management of hypotension after a bolus of 
Syntocinon® IV was administered? 
_________________________________________________________________________ 
9. What agent is an oxytocin antagonist indicated for tocolysis in labour? 
_________________________________________________________________________
_________________________________________________________ 
10. What dose of Syntocinon® IV do you use in an uncomplicated caesarean section under 
spinal anaesthesiology? 
___________________________________________________________ 
11. Do you use Syntocinon® IV (bolus or infusion) during Caesarean section under spinal 
anaesthesia? 
Yes with every 
Caesarean section 
 Yes but only when 
indicated by the 
surgeon 
No but other 
uterotonic drugs 
are used instead  
No never 
 
12. How do you administer Syntocinon® IV? 
        Bolus    Infusion Bolus and Infusion 
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Appendix Three: Approval from Ethics Committee 
 
 
